Osteoarthritis (OA) is driven by senescent chondrocytes (cartilage cells) that lose their anabolic matrix-building functions and shift to a catabolic SASP-secreting state, producing MMP-13, MMP-3, IL-1β, and IL-6. A Mayo Clinic preclinical study demonstrated that D+Q reduced OA pathology in a mouse model; a Phase 2 human trial is now evaluating D+Q for OA.

Can senolytics replace NSAIDs for joint pain?

Senolytics address the underlying cellular mechanism of OA; NSAIDs suppress symptoms. Senolytics are not immediate pain relievers — effects on OA symptoms would build over months as senescent chondrocyte burden is reduced. Both have complementary roles.

Is intraarticular (joint injection) senolytic delivery being studied?

Yes. Local intraarticular delivery of D+Q, fisetin, and navitoclax is being evaluated in preclinical models. Local delivery provides high joint concentrations while minimizing systemic exposure — particularly appealing for the OA indication.